Cullumber Pharmaceuticals entered into a licensing agreement with Zenith Lab for a new drug under development. Cullumber will receive $ if the new drug receives FDA approval. Based on prior approval, Cullumber determines that it is likely that the drug will gain approval. The transaction price of this arrangement should be